# A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

> **NCT03166878** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- B Cell Leukemia
- B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** UCART019

## Key facts

- **NCT ID:** NCT03166878
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06
- **Primary completion:** 2022-05
- **Final completion:** 2022-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166878, "A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03166878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*